Member Info for Fredd1eboy

Agnostic. I cannot understand either, but what I do know is that we are funding big salaries both within the company and outside of it. I also come from a TQM background which ultimately rates the success of a publically listed company on shareholder value. Enough said by yours truly

fair point sheer but mune is only aimed at the bod, olav in particular.

. .Several more positive posts...please read before further Rene bashing

Just imagine how you would have felt if you had a trade order on at 10p

.I've now made my point over several posts. The same message has been driven home by many of us. As mol quite rightly says...the BOD read posts and can therefore plan mindful of all opinions. I'm now backing off awaiting a change in strategy aimed at delivering added value to the sp. Best wishes all. Freddie

5p = �5

....Wish the interviewer had asked Micheal how he expects to fund these trials to end 2019 . Come on Neil Woodford and buy us out at the 5p /share you paid for 36% of the company. You recently said its grossly undervalued so why not put the offer in. You are then in total control of your own destiny. Bet you could also find a better CEO. Freddie

The results are impressive.....market response zilch.....poor leadership is responsible,,,, , my investment is wrecked due to Research to date valued at zero....thats down to you Mr Hellebo.and your 70% useless board, Please ask Woodie to put his money where his mouth is and buy you out at �5.oo.....his valuation over 2 years ago

Reminder c/o mol iii site 27 October 2017 AIM: RENE ReNeuron Group plc ReNeuron wins further UK grant to advance its exosome therapy platform is pleased to announce that it is the lead industry participant in a new grant award from the Welsh Government to advance its emerging exosome therapy platform. The grant has been awarded under the Welsh Government�s SMARTExpertise scheme and will help fund a �1.2m collaborative programme of work to be undertaken by ReNeuron, Ig Innovations and Swansea University Medical School. The work programme will establish methods to refine and optimise the manufacturing process for generating ReNeuron�s CTX cell-derived exosomes with the highest biological efficacy, methods to enhance the characterisation of the CTX-derived exosomes against solid tumours to identify new cancer targets, and methods to characterise exosomes with potential therapeutic benefit derived from ReNeuron�s broader proprietary cell line library. ReNeuron is exploiting its exosome therapy platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action. The SMARTExpertise grant follows the award of a grant to ReNeuron last year from Innovate UK to develop manufacturing systems and to conduct pre-clinical testing relating to the Company�s exosome therapy platform. Commenting on the grant award, Dr Randolph Corteling, Head of Research at ReNeuron, said: �We are delighted to have won this new grant under the Welsh Government�s SMARTExpertise scheme. As a Wales-based business, we are very pleased to be able to work with leading Welsh academic and industry collaborators in order to further progress development of our high-potential exosome therapy platform towards clinical application.� Mol

In May 2017, Tessa was found to have a high-grade brain tumour known as glioblastoma. Isn't that the cancer Reneuron is partnering exosomes on mainland Europe? Perhaps todays search may act as a development catalyst ....

Excellent clip GR. I will paste on iii. Best wishes. Fred

http://www.lse.co.uk/Level2SharePrice.asp?shareprice=RENE&share=reneuron Oh if it were true!!

Wouldn't it be wonderful if the buyers were actually members of the BOD. In the event my entire attitude towards the company leadership would change....for the better

But it's what happens long-term that matters, so if NASDAQ happens and we access lots of funding and the price goes to a pound, I won't care about how we got there! I'll agree with you on that one jackdaw......albeit a very long term for me!

Hi Jackdaw. Thanks for putting me straight. It's just that every time I read of a BOD purchasing shares in the company they run, I look back at the Rene BOD with contempt. Only two have bothered to buy over the past years and one of them also sold a load. My frustration overfloweth with anger....I've supported over the years and now realize they couldn't give a monkey's about us small fry.

. OXB.....shame on you Reneuron BOD!

Cannot but envy your investment strategy for Reneuron Morris. I could kick myself for not doing the same but held on for better things to come. I honestly believe that even if all Rens001.003,009 don't make it to market, exosomes manufacturing will save our bacon and very probably lead to a good profit. That said, I still regret not selling out at 6p....thats hindsight for you. Best wishes and good luck to you but don't dismiss Reneuron. At the current price, I still think its got room to move up. Just needs someone good at the helm ....hellebo go!

Thats ridiculous morrisminor. I lost a packet on Angel and remember it well. SP collapse due to starvation of funds, delays to licensing of stem cell research lab....poor product mix...hair and skin replacement. Dodgey Russian contract........says it all. Rene has funds, credible backers good product mix.....etc etc. News due this year on several fronts....its just suffering from uninterested short term aim market investors.

Process vs Reneuron....performance....well cobalt your thoughts.. Any further thoughts on Valirx. Best wishes. Freddie

Help, board, achieve....I haven't seen any evidence since woodford invested....in fact I'm sick of them....thank goodness the boffins are delivering....as for the rest I'd sack then all and start again.